LISBON, Portugal, May 4, 2021 | PRNewswire | Piauhy Labs, one of Portugal's leading biotech & medical cannabis firms has completed its latest funding round led by Migration Capital, a private investment company based in the Greater Boston Area focused primarily on disruptive and innovative sectors, positioned for exponential growth, such as Biotech. This investment represents one of the most important cannabis financing rounds in Portugal to date.
"We have been evaluating opportunities in the Cannabis space for several years and Piauhy's scientific approach to medical cannabis aligned well with our investment philosophy. We are very impressed with the scientific endeavors of the company, its capital efficiency and the wonderful timing of the European medical cannabis market”. Our investment, combined with the expertise of the company's team, led by its CEO, Eduardo Sampaio, will thrust Piauhy’s growth and differentiation from other companies in the medicinal cannabis industry ", said Estevao Latini, Director of Alternative Investments of Migration Capital.
“We are very happy with this important milestone and delighted that Migration's focus on disruptive innovations matched our ambitions. We are at the crossroads of biotech, neurosciences and medical cannabis”, says Eduardo Sampaio, CEO and founder. “The success of Piauhy Labs is intrinsically linked to the world-class scientific research we are leading in partnership with local universities and scientific partners in Portugal, Brazil and California. We are building a pharmaceutical company for the future where personalized medicine is crafted to the patient’s genetics and epigenetics characteristics”.
LISBON, Portugal, May 4, 2021 | PRNewswire | Piauhy Labs, one of Portugal's leading biotech & medical cannabis firms has completed its latest funding round led by Migration Capital, a private investment company based in the Greater Boston Area focused primarily on disruptive and innovative sectors, positioned for exponential growth, such as Biotech. This investment represents one of the most important cannabis financing rounds in Portugal to date.
"We have been evaluating opportunities in the Cannabis space for several years and Piauhy's scientific approach to medical cannabis aligned well with our investment philosophy. We are very impressed with the scientific endeavors of the company, its capital efficiency and the wonderful timing of the European medical cannabis market”. Our investment, combined with the expertise of the company's team, led by its CEO, Eduardo Sampaio, will thrust Piauhy’s growth and differentiation from other companies in the medicinal cannabis industry ", said Estevao Latini, Director of Alternative Investments of Migration Capital.
“We are very happy with this important milestone and delighted that Migration's focus on disruptive innovations matched our ambitions. We are at the crossroads of biotech, neurosciences and medical cannabis”, says Eduardo Sampaio, CEO and founder. “The success of Piauhy Labs is intrinsically linked to the world-class scientific research we are leading in partnership with local universities and scientific partners in Portugal, Brazil and California. We are building a pharmaceutical company for the future where personalized medicine is crafted to the patient’s genetics and epigenetics characteristics”.
An European based science driven medical cannabis company, committed to producing high quality, personalized medicine – Positioned at the crossroad of biotechnology, neuroscience, and medicinal cannabis.
See the release